ParaPRO

ParaPRO is a U.S.-based commercial-stage biotech company addressing parasitic infestations with its lead product, Natroba™ (spinosad) Topical Suspension 0.9%, a prescription treatment for head lice. The company's strategy is built on commercializing the unique spinosad compound, for which it holds a license from Eli Lilly/Corteva, and supporting the professional community with educational resources. It operates as a lean, privately held organization targeting a niche but persistent market with a significant need due to growing resistance to older therapies. ParaPRO's outlook is tied to the sustained commercial performance of Natroba and potential expansion of its spinosad-based portfolio.

Development and commercialization of therapeutics based on the naturally derived spinosad compound, a mixture of spinosyns A and D with a novel dual mechanism of action (nicotinic acetylcholine receptor and GABA receptor modulation) that avoids cross-resistance with traditional pediculicides.

ParaPRO competes in the prescription head lice segment against other Rx products like ivermectin lotion (Sklice) and benzyl alcohol lotion (Ulesfia), as well as the large but increasingly ineffective OTC market dominated by permethrin/pyrethrin products. Its key differentiator is spinosad's unique mechanism with no known resistance, giving it a strong clinical and marketing advantage.